medullary thyroid cancer
Oncology · 2026–2026
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| selpercatinib Treatment of locally advanced or metastatic medullary thyroid cancer (MTC) in patients with RET variants who have unresectable disease and documented disease… | Mar 2026 | Deferred | 8 individuals Rare Cancers Australia |
Who spoke
Rare Cancers Australia
What the PBS pays
$1M in government benefit over 2024–25, across 95 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| selpercatinib | $0.6M |
Appraised elsewhere
NICE, in England and Wales, has appraised 2 technologies for this condition, recommending 1 and declining 1. A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| vandetanibCAPRELSA vandetanib 100mg film coated tablet blister pack | 2013 | 1 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.